Selective inhibition of herpes simplex virus (HSV) type 1 replication but not of HSV type 2 replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was utilized to differentiate clinical isolates of these viruses. BVDU (0.7 ,ug/ml) reduced HSV type 1 PFU by an average of 2.74 log1o, but had no effect on the plaque-forming ability of HSV type 2 isolates. The incorporation of BVDU into the media of primary cell cultures used for virus isolation in the clinical laboratory allowed for the correct presumptive identification of HSV types.
Many antiviral compounds which possess specific antiherpetic activity in vitro have been described. De Clercq et al. (1) compared more than 20 antiherpetic drugs against several strains of herpes simplex virus (HSV) in rabbit kidney (RK) cells. Although several of the drugs are more effective against HSV type 1 (HSV-1) than HSV type 2 (HSV-2), the most significant differences are demonstrated by (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and (E)-5-(2-iodovinyl)-2'-deoxyuridine. These compounds inhibit HSV-2 strains at concentrations more than 100 times greater than those required to inhibit HSV-1 strains. The authors stated that this differential sensitivity can be a useful marker test for the differentiation of HSV-1 and HSV-2 strains. The present report compares the use of BVDU sensitivity as a marker with a selective cell culture system which has been used routinely in this laboratory for typing HSV strains (6) . Included also are the results of the incorporation of BVDU directly into the culture media of cells inoculated with clinical specimens suspected to contain HSV.
Primary RK cells, guinea pig embryo (GPE) cells, and chicken embryo (CE) cells were prepared by standard laboratory procedures (4). The selective cell culture system for typing HSV strains has been described previously (6) . Brief 34°C for 4 days, and stained, and plaques were counted with a microscope. HSV-2 isolates produce plaques in both CE and GPE cells, whereas HSV-1 isolates produce plaques only in GPE cells.
Clinical specimens which had been submitted for virus isolation were stored at -70°C and used directly for HSV typing or were passaged once in RK or GPE cells. A few laboratory strains of HSV were provided by B. Francke, Yale University School of Medicine, New Haven, Conn. BVDU was kindly provided by E. DeClercq, Rega Institute for Medical Research, Leuven, Belgium. The drug was suspended in sterile phosphate-buffered saline at a concentration of 500 ,ug/ml, dispersed in 1-ml aliquots, and stored at -70°C. The sensitivity of HSV isolates to BVDU was determined by incorporating 0.7 ,ug of BVDU per ml into the overlay medium of inoculated GPE cell monolayers titrated simultaneously with the cell selection system described above. For a test of the ability of BVDU to differentiate between HSV-1 and HSV-2 upon the initial isolation of the viruses, the same concentration of drug (0.7 ,ug/ml) was added to the culture medium of two RK or GPE cell tubes inoculated with clinical material from suspected HSV cases. These tubes were used in addition to RK or GPE cells without drug and to commercially available human embryo fibroblasts (WI-38 or MRC-5). All tubes were held for 2 weeks before beingjudged as negative. The appearance of characteristic herpes-like cytopathic effects (CPE) in RK or GPE cell tubes with and without the drug was considered a presumptive HSV-2 isolation, whereas the appearance of characteristic CPE only in tubes without the drug was a presumptive HSV-1 isolation. All isolates were HSV-1 a BVDU (0.7 ,ug/ml) was added directly to culture media of cells used for the primary isolation of HSV from clinical specimens (see text).
b, no CPE during the entire observation period.
Misidentified preliminarily; subsequently typed as HSV-1 (see Table 1 ).
included in these calculations but were added only for reference. Table 1 also shows the results of the titrations of 21 HSV-2 strains under the identical conditions used for the HSV-1 experiments. There was no significant effect of BVDU on the plaque-forming ability of any of the HSV-2 strains. All strains were identified as HSV-1 or HSV-2 by titration in the selective cell culture system which was run in parallel with the drug studies. In addition, approximately 50% of each HSV type was analyzed for its ability to induce deoxypyrimidine triphosphatase, an HSV-1-specific enzyme (8 (Table 2 ). In 17 of 18 isolations, the presumptive identification was correct when the isolates were subsequently tested by the selective cell culture and BVDU sensitivity methods. The isolate which was initially misidentified is the only specimen in Table  2 that was collected directly from the patient while in the clinical virology laboratory and inoculated undiluted into appropriate cell cultures within seconds of collection. This suggests, quite expectedly, that the effects of a limited amount of drug can be overcome by very high titers of virus. The problem can be overcome by the dilution of specimens suspected to be of high titers, such as those collected in the laboratory or inoculated at the bedside, into the appropriate cell cultures.
Herpes simplex viruses are the most frequently isolated viruses in this laboratory (5) and in the majority of clinical virology laboratories (7) . The identification of these viruses as HSV-1 or HSV-2 is important for patient management and counseling purposes (5, 6) . Typing of HSV isolates may assume even greater importance when antiviral agents with varying effectiveness against HSV-1 or HSV-2 (1) become more widely available. In the present studies, all isolates of HSV whose ability to form plaques was inhibited by at least 2 logl0 by BVDU were identified as HSV-1 by the selective cell method. Similarly, the isolates of HSV which were not inhibited by BVDU were all identified as HSV-2 by this CE-GPE method.
The question of the emergence of BVDUresistant HSV-1 strains must be raised since this would lead to the misidentification of HSV strains. No BVDU-resistant HSV-1 strains have been described. The search for naturally occurring drug-resistant mutants to another more widely used and investigated antiviral drug, acycloguanosine [9-(2-hydroxyethoxymethyl)gua-J. CLIN. MICROBIOL. nine], has been unsuccessful. Experimentally, it has not yet been possible to induce acycloguanosine-resistant HSV mutants in vivo, apparently because such mutants that may arise do not thrive (2) . However, treatment-resistant strains of HSV have been isolated from patients who have undergone prolonged therapy with 5-iodo-2'-deoxyuridine (3).
All of the BVDU sensitivity determinations done in this study used GPE cells; however, several virus strains were also typed using RK cells. As expected, the results were identical since the work which described the specific effect of BVDU on HSV-1 was performed in RK cells (1 
